UK Medical Research Regulators Spared the Axe
By Daniel Cressey,
Nature News Blog
| 07. 18. 2013
The future of the UK regulating bodies for human-embryo and human-tissue research has been safeguarded, as the government’s announcement yesterday that the two bodies will continue to exist brings a long-running saga to an end.
Back in 2010 the government said that it would axe the Human Fertilisation and Embryology Authority (HFEA), which regulates research on human embryos and fertility treatment. The Human Tissue Authority (HTA), which regulates other human tissue research and organ donation, was also to be wound up. The proposals were unpopular with many researchers, and
earlier this year the Department of Health announced that instead it would commission an independent review to see whether the two bodies could be merged.
That review —
published yesterday — found that there was “relatively little overlap” in the work of the two regulators and they should continue as separate bodies. This outcome has been
accepted by the government.
There will be some changes for researchers. Regulation of tissue used for developing medicinal products is to be transferred from the HTA to the UK Medicines and Healthcare Products Regulatory...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...